Organisation paid for research Program year 2025 Source: CMS Open Payments

Sierra Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$2,291,079

441 payments

Through program year 2025, Sierra Clinical Research is reported as receiving $2,291,079 in research payments, across 441 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $139,296 5
2024 Research $205,833 31
2023 Research $135,601 24
2022 Research $187,664 29
2021 Research $295,542 209
2020 Research $519,743 71
2019 Research $807,400 72

Breakdown

Who paid Research payments · program years 2019–2025
  1. Amgen Inc. $662,870 15 payments
  2. AstraZeneca Pharmaceuticals LP $423,932 12 payments
  3. Allergan Inc. $300,373 31 payments
  4. Intercept Pharmaceuticals, Inc. $234,164 43 payments
  5. Mylan Specialty L.P. $147,282 12 payments
  6. Sanofi US Services Inc. $145,953 34 payments
  7. Chiesi USA, Inc. $114,136 24 payments
  8. Janssen Research & Development, LLC $59,565 16 payments
  9. Eli Lilly and Company $59,456 20 payments
  10. GlaxoSmithKline, LLC. $52,112 16 payments
Studies the money was for Research payments · program years 2019–2025
  1. FOURIER OLE (Ph 4) $449,278 6 payments
  2. AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $194,033 14 payments
  3. A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma $168,860 4 payments
  4. 1009742 $149,244 21 payments
  5. A Phase 2a Randomised Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA $135,757 2 payments
  6. 20160250-FOURIER OLE (Ph 4) $132,287 2 payments
  7. A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler $106,752 3 payments
  8. A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) $98,322 10 payments
  9. Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) $91,280 25 payments
  10. A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) $75,985 21 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record